Physician profile
Mark E Ward
NPI 1194791061
$1,553.66
in general payments reported to CMS, 2019-2025
32 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.58 · 2020: $68.43 · 2021: $200 · 2022: $572 · 2023: $322 · 2024: $97.50 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $261.45 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $147.21 | 2021-2025 | |
| Abbvie INC. | $131.07 | 2022-2023 | Ubrelvy, Vraylar |
| Amgen INC. | $115.92 | 2021-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $96.93 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $91.14 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $85.05 | 2021-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $74.88 | 2022 | |
| Glaxosmithkline, LLC. | $55.52 | 2022-2023 | Arexvy, Trelegy Ellipta |
| Alnylam Pharmaceuticals INC. | $53.01 | 2022 | |
| Abbott Laboratories | $35.15 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $31.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.41 | 2020 | |
| Ascensia Diabetes Care US INC. | $24.69 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.00 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.90 | 2021 | |
| Antares Pharma, INC. | $22.38 | 2022 | |
| Merck Sharp & Dohme LLC | $21.14 | 2022 | |
| Inari Medical, INC. | $20.78 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $20.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.37 | 2023 | Camzyos |
| Eisai INC. | $19.28 | 2021 | |
| Esperion Therapeutics, INC. | $17.23 | 2022 | |
| Hikma Pharmaceuticals USA | $15.88 | 2023 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.04 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.38 | 2019 | |
| Amarin Pharma, INC. | $12.36 | 2020 | |
| Novo Nordisk INC | $12.35 | 2022 | |
| Allergan, INC. | $11.85 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.